Sulfonamide Compound RNR Inhibition Without Metal Chelation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNR inhibitors, such as hydroxyurea and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, have limited efficacy and side effects due to weak RNR inhibitory activity and off-target effects, necessitating the development of a compound with improved RNR inhibitory activity and no metal ion chelation capability for cancer treatment.
Innovation Solution
A novel sulfonamide compound with a specific structure, represented by formula (I), which selectively inhibits ribonucleotide reductase (RNR) and is useful as an antitumor agent, exhibiting excellent RNR-inhibiting activity without chelating metal ions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxyurea is used as an RNR inhibitor, then it has been used clinically for over 30 years, but its RNR inhibitory activity is very weak and its effect is limited
Solution Approach 1:
The patent modifies the chemical structure of RNR inhibitors by changing key parameters - specifically using sulfonamide compounds with defined molecular structures (formula I) featuring specific substituents (R1-R4, X1-X4) to achieve enhanced RNR inhibitory activity compared to conventional hydroxyurea
Solution Approach 2:
The invention employs composite chemical structures combining sulfonamide core with specific aromatic and heterocyclic substituents (such as phenyl, pyridine, triazole groups) to create a multi-functional molecule that simultaneously achieves strong RNR inhibition and desirable pharmacological properties
2Manufacturing precision
If 3-aminopyridine-2-carboxaldehyde thiosemicarbazone is used as an RNR inhibitor, then it has RNR inhibitory activity, but it chelates to metal ions causing off-target effects and side effects
Solution Approach 1:
The patent extracts and removes the metal ion chelating capability from the molecular structure by avoiding use of thiosemicarbazone moieties and instead employing sulfonamide compounds that do not have affinity for metal ions, thereby eliminating off-target effects while maintaining RNR inhibition
Solution Approach 2:
The invention converts the potential harm of metal ion chelation (which causes off-target effects) into a benefit by designing sulfonamide compounds that selectively inhibit RNR without chelating metal ions, thus achieving specific activity without the harmful side effects associated with non-specific metal binding
Data Source
AI summary
The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.